An open label study of MDX-CTLA4 [ipilimumab] in combination with tyrosinase/gp100/MART-1 peptides [melanoma vaccine] emulsified with monatide ISA 51 in the treatment of patients with resected stage III or IV melanoma

Trial Profile

An open label study of MDX-CTLA4 [ipilimumab] in combination with tyrosinase/gp100/MART-1 peptides [melanoma vaccine] emulsified with monatide ISA 51 in the treatment of patients with resected stage III or IV melanoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Sep 2013

At a glance

  • Drugs Ipilimumab (Primary) ; Interleukin-12; Melanoma vaccine; Montanide ISA-51
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top